Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Opko

This page shows the latest Opko news and features for those working in and with pharma, biotech and healthcare.

Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate

Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate

commercialisation. In exchange, Opko will receive an upfront payment of $50m and will be eligible for milestone payments of up to $872.5m plus royalties on global sales. ... The agreement follows Opko’s recent acquisition of ModeX, a biopharma and

Latest news

  • Versartis crashes as VELOCITY trial veers off track Versartis crashes as VELOCITY trial veers off track

    It’s not the first long-acting hGH to miss the mark in trials - earlier this year Pfizer and Opko’s once-weekly candidate also failed a phase III trial.

  • Pfizer/Opko's long-acting growth hormone misses mark in trial Pfizer/Opko's long-acting growth hormone misses mark in trial

    Pfizer and partner Opko ended 2016 on a disappointing note after their long-acting drug for growth hormone deficiency failed a phase III trial. ... Opko put a brave face on the finding, saying it could have been skewed by "one or more outliers" that

  • Pfizer buys majority stake in Redvax Pfizer buys majority stake in Redvax

    No financial details of the deal have been disclosed. This rounds off a busy M&A period for Pfizer which just a fortnight ago partnered with Opko Health on a late

  • RNA interference rebirth RNA interference rebirth

    TTR. TTR-mediated amyloidosis. I. TKM-ApoB. Tekmira. ApoB. hypercholesterolaemia. Stalled. bevasiranib. Opko Health.

  • Flicking the switch

    Opko Health is developing bevasiranib for the treatment for wet age-related macular degeneration (AMD). ... In phase II trials, bevasiranib inhibited the growth of choroidal neovascularisation and Opko have now initiated a pivotal phase III trial that

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    The manufacturing CRLs have been out in force and AstraZeneca is not the only company on the receiving end with OPKO receiving a CRL earlier in the year [March] in relation ... 293. OPKO Health/ Vifor Fresenius. Licence. Rayaldee in EP, CA, Mexico,

  • Pharma deals in June 2015 Pharma deals in June 2015

    Opko's strategy in its $1.47bn acquisition of Bio-Reference Laboratories at $52.58 per share (approximately 60% premium) is to gain access to a range of diagnostic capabilities including ... Acquisition - company. 2, 050. Bio-Reference Laboratories/ OPKO

  • Pharma deals during December 2014 Pharma deals during December 2014

    This product, named hGH-CTP, was in the portfolio of Prolor Biotech which Opko acquired in August 2013 for $480m. ... The upfront payment of $295m from Pfizer will go some of the way to recoup the price Opko paid for Prolor.

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Collaboration, licence. 581. Opko Health / Pfizer. Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • AstraZeneca appoints head of oncology AstraZeneca appoints head of oncology

    Prior to this, Dr Freedman served as GlaxoSmithKline's vice president of oncology R&D, and led OPKO Health's R&D department.

  • OPKO appoints vice president of medical affairs OPKO appoints vice president of medical affairs

    Dr Douglass Laidlaw brings experience from Relypsa and Sanofi. Miami-based OPKO Health has appointed Dr Douglass Laidlaw as vice president of medical affairs. ... Philip Frost, chairman and chief executive of OPKO, said: “Doug is a key addition to the

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Because health means everything...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...

Quick links